ESMO COLLOQUIUM - Hepatocellular carcinoma treatment: Now, next and beyond
- Introduction (Jean-Luc Raoul)
- Pros and cons of loco-regional therapy options (Carlos Gomez Martin)
- Transitioning to first line systemic treatment; Pros and Cons of initiating early systemic treatment? (Lorenza Rimassa)
- Moving beyond monotherapy in first line HCC: What will be the new standard for the expected clinical and patient outcomes? (Arndt Vogel)
- Summary and conclusion* (Jean-Luc Raoul)
This educational activity is provided by ESMO and supported by Eisai.
View the ESMO colloquium details
ESMO COLLOQUIUM - Systemic therapies in unresectable hepatocellular carcinoma (HCC): 1st and later lines
- Introduction* (Peter R. Galle)
- Targets Biology in HCC (Jean-Luc Raoul)
- Targeted agents in unresectable HCC: a review of results in 1st and 2nd line (Lorenza Rimassa)
- Emerging Immunotherapy in unresectable HCC* (Bruno Sangro)
- Future systemic treatments: new agents, targeted drug-combination, immune-drug combination?* (Jordi Bruix)
- Conclusion* (Peter R. Galle)
This educational activity is provided by ESMO and supported by IPSEN.
View the ESMO colloquium details
ESMO COLLOQUIUM - Immune check point inhibitors: Are we ready for combination?
- Introduction* (John B. Haanen)
- Mechanisms of chemotherapy-induced increased immune response (Johan F. Vansteenkiste)
- Achievements and present development in lung cancer (Marina C. Garassino)
- Where do we stand in TNBC breast cancer? (Sherene Loi)
- Which patients do benefit? How to select and for which benefit? (John B. Haanen)
- Conclusion* (John B. Haanen)
This educational activity is provided by ESMO and supported by Celgene.
View the ESMO colloquium details
ESMO COLLOQUIUM - Acute Myeloid Leukemia – Focus on FLT3-ITD mutation
- Introduction* (Jorge E. Cortes)
- Molecular profile of AML and prognostication/risk classification (Lars Bullinger)
- Are present clinical practice GL for the management of AML obsolete?* (Michael Heuser)
- FLT3-ITD mutated AML: A special entity? (Klaus H. Metzeler)
- New approaches on the management of relapsed or refractory FLT3-ITD mutated AML (Jorge E. Cortes)
- Conclusion* (Jorge E. Cortes)
This educational activity is provided by ESMO and supported by Daiichi Sankyo.
View the ESMO colloquium details
ESMO COLLOQUIUM - Are biosimilars the key to access, in practice?
- Introduction (E.G. Elisabeth De Vries)
- Acceptance of oncology biosimilars in supportive care: a success story (Martina Weiss)
- Existing challenges for uptake of oncology biosimilars – ESMO survey results (Malvika Vyas)
- In practice (UK): patients being switched from a biologic to a biosimilar - UK (Stephen Scowcroft)
- One year on – state of play in the EU on oncology biosimilars (Murray Aitken)
- Supplementary Protection Certificates & their potential impact on availability of biosimilars* (Roberto Romandini)
- Conclusion* (E.G. Elisabeth De Vries)
This educational activity is provided by ESMO and supported by Amgen, MSD, Pfizer and Sandoz.
View the ESMO colloquium details
*Resources are not available.